Patent ID: 8846311
Filing Date: 2014-09-30
Classification: C12Q,G01N

Abstract:
1. A method for identifying an agent as a potential inhibitor of GLK-mediated NF-κB activity for treating a Germinal Center Kinase (GCK)-Like Kinase (GLK)-mediated disease, comprising: a) culturing GLK-expressing cells in the presence of the test agent; b) measuring the activity of NF-κB or the amount of IL-17A produced; c) comparing the activity of the NF-κB or the amount of the IL-17A produced in the presence of the test agent with a control; and d) identifying the agent as the potential inhibitor of the GLK-mediated NF-κB activity for treating the GLK-mediated disease when there is a reduction of the activity of NF-κB or the amount of IL-17A in the presence of the test agent.